Introduction
Adenoviruses have utility for gene therapy because these vectors have a wide spectrum of tissue infectivity, can be produced in high titers, and are easily genetically modified.
1,2 Viral vectors function by replicating to toxic levels within infected cells or by delivering a 'suicide gene' encoding enzymes to locally modify systemically administered non-toxic drugs into their toxic metabolites. 3, 4 Additionally, therapeutic genes inserted into the vector may be infected into specific host tissues to produce a biological effect. 5, 6 However, most viral vectors do not preferentially infect tumor cells. To prevent viral replication and subsequent toxicity to normal tissues, the E1A gene, which is critical for adenoviral replication, is frequently deleted. A replication-deficient vector is one strategy employed to modify adenoviruses for in vivo investigations and potential human trials. However, the antitumor efficacy of a replication-deficient adenovirus is limited by the inability to reproduce and spread its progeny to infect neighboring tumor cells.
To circumvent this limitation, tissue-specific promoters have been employed to exploit specific tumor characteristics, such as the expression of tumor-specific proteins. 7 To enhance the selectivity and efficiency of viral replication, transcription segments from the carcinoembryonic antigen (CEA), 8 prostate-specific antigen (PSA) 9 and alpha-feto protein (AFP) 10 genes are inserted upstream of the E1A gene to drive viral replication in tumors responsible for producing the characteristic proteins and thereby convert replication-deficient vectors to conditionally replication-competent vectors. For example, the CEA promoter, activated by transcription factors responsible for CEA production in colon carcinomas and ligated upstream of the adenoviral gene E1A, mediates viral replication selectively within CEA-producing colon carcinoma cells.
The first studies on the control of mammalian cell gene expression by ionizing radiation (IR) were reported by Hallahan et al 11, 12 and Sherman et al. 13, 14 The response of c-jun and Egr-1 to IR has been reported in detail by Datta et al. [15] [16] [17] The general motif for transcriptional induction by IR was determined to be through modification of transcription factors by a cellular kinase and hence binding of these factors to cognate elements in the promoter/enhancer regions of Egr-1 or c-jun. DF3/MUC1 (DF3) is a high molecular weight glycoprotein that consists of peptide tandem repeats containing threonine and serine residues, which are potential sites for glycosylation. 18 Late in carcinogenesis, hypoglycosylation of DF3 leads to its aberrant overexpression in a wide variety of epithelial cancers including breast, ovary, and gastrointestinal malignancies. 19 We have previously demonstrated that an adenoviral vector can be modified to be conditionally replication competent in a DF3-positive breast carcinoma model. 20 In the present study, we investigated the potential efficacy of the DF3 promoter to selectively enhance viral replication and therapeutic gene delivery in DF3-producing esophageal cancer cells. Tumor necrosis factor alpha (TNF-a) was selected as a potential therapeutic gene because of its antitumor and radiosensitizing properties based on investigations of gene therapy with vectors encoding TNF-a combined with IR. 21, 22 We also studied the interactive cytotoxic effects of TNF-a and IR in vivo in DF3-positive Bic-1 and DF3-negative Seg-1, human esophageal adenocarcinoma xenografts.
Results

DF3/MUC1 expression in Seg-1 and Bic-1 cell lines
The expression of DF3/MUC1 in the Seg-1 and Bic-1 cell lines was assessed by flow cytometric analysis with an anti-MUC1 antibody (Figure 1 ). Human embryonic kidney fibroblast 293 cells (a) demonstrated minimal DF3/MUC1 expression compared to the isotype-identical control and therefore served as a negative control. The MCF-7 breast carcinoma cell line (b) exhibited strong DF3/MUC1 expression and served as a positive control. DF3/MUC1 was moderately expressed in Bic-1 human esophageal adenocarcinoma cells (c), but was undetectable in Seg-1 human esophageal adenocarcinoma cells (d).
TNF-a production suggests selective viral replication in DF3/MUC1-producing cells
Bic-1 and Seg-1 human esophageal adenocarcinoma cells were infected in vitro with Ad.DF3. TNF at 0.001 MOI and TNF-a production was quantified to indicate viral replication and evaluate TNF-a expression. hTNF-a ELISA of the conditioned medium from Bic-1 cultures and Seg-1 cultures reveals equivalent TNF-a secretion at days 1 and 2 ( Figure 2 ) demonstrating the constitutive activity of the CMV promoter. However, by day 5 the greater than 50-fold increase in TNF-a produced by the Bic-1 (DF3+) cell line compared to the Seg-1 (DF3À) cell line (141 200+60 000 versus 2200+800 pg/ml, respectively) suggests enhanced viral replication, increased TNF-a gene expression and, subsequently, greater TNF-a production in the DF3-producing cell line (Bic-1) compared to the non-producers (Seg-1). These findings are in agreement with those published by Kurihara et al. Selective gene expression using a DF3/MUC1 VK Gupta et al Particle units (pu)) harvested at day 7 demonstrate a 50-fold increase in TNF-a production in the Bic-1 xenografts as compared to the Seg-1 xenografts (range: 804.3-3465.1 versus 29.1-37.4 pg/mg of protein, respectively, Figure 3 ). The broad range in TNF-a levels observed in these studies is related to the number of tumor cells infected by the adenoviral vector following intratumoral injection. It has been documented that vectors do not diffuse within the tumor volume but rather locate along the needle tract. To circumvent this problem, we inject the tumor in multiple sites. The small amount of TNF-a produced in the Seg-1 xenograft homogenates indicates non-selective adenoviral infection and the basal constitutive TNF-a expression under the control of the CMV promoter. Our in vivo data support the in vitro findings and suggest enhanced viral replication that is indicated by greater TNF-a gene expression in Bic-1 (DF3+) xenografts compared with the Seg-1 (DF3À) xenografts.
Histology suggests enhanced viral replication in DF3/ MUC1-producing xenografts
Bic-1 and Seg-1 xenografts treated with either the vector containing a null virus tagged with green fluorescence protein (Ad.DF3. GFP) or the TNF-a gene (Ad.DF3.TNF) were harvested at day 21 and examined with immunofluorescence ( Figure 4 ). Enhanced green fluorescence staining was apparent in Ad.DF3.GFP-treated Bic-1 xenograft sections (b) suggesting continued viral replication as compared to the absence of signal in the Seg-1 xenografts (a). Loss of nuclear architecture following DAPI staining in Ad.DF3.TNF treated Bic-1 sections (d) suggests enhanced viral replication and/or cell death as compared to the normal rounded nuclear appearance in the Seg-1 xenografts (c). These findings further demonstrate the selectivity of the DF3 promoter to direct viral replication and therapeutic gene expression within Bic-1 (DF3+) xenografts compared with Seg-1 (DF3À) xenografts.
Enhanced TNF-a production in Bic-1 xenografts increases antitumor effects of IR
To determine the potential effects of enhanced antitumor selective viral replication and enhanced TNF-a gene expression in vivo, we randomized athymic nude mice bearing Seg-1 (DF3À) xenografts to one of six treatment groups. Following administration of treatment, mean fractional tumor volumes were determined (Figure 5a ). No significant difference in mean tumor volume was detected between the control groups (buffer, null virus alone, or Ad.DF3.TNF alone). No effect on tumor growth was detected following treatment with IR alone, null virus +IR or Ad.DF3.TNF+IR. These findings suggest a lack of TNF-a gene expression in the Seg-1 (DF3À) xenografts.
By comparison, Bic-1 xenografts ( Figure 5b ) treated with either the null virus or Ad.DF3.TNF demonstrated a nine-day growth delay compared to buffer-treated controls. However, TNF-a expression in Ad.DF3.TNFtreated xenografts did not alter the regrowth pattern compared to xenografts treated with the null virus. Importantly, combined treatment with Ad.DF3.TNF+IR produced significant tumor regression compared to treatment with Ad.DF3.Null+IR. The combined effect of TNF-a and IR significantly reduced mean tumor volume by 40% after day 22 (P o 0.05) and resulted in an increased growth delay of 19 days compared to 7 days in the Ad.DF3.Null+IR group.
Discussion
Analyses of the Surveillance, Epidemiology, and End Results (SEER) database report that the incidence of esophageal adenocarcinoma is rapidly increasing and greatest in caucasian males. [23] [24] [25] Risk factors for esophageal adenocarcinoma include gastroesophageal reflux disease, obesity, and Barrett's esophagus. Despite the use of multi-modality therapy, median overall survival remains dismal at 12-15 months. However, a minority Selective gene expression using a DF3/MUC1 VK Gupta et al of patients with esophageal adenocarcinoma have a complete pathologic response to preoperative induction chemo-radiotherapy. Subset analyses demonstrate that only true complete responders have a durable diseasefree and overall survival benefit. [26] [27] [28] [29] The addition of gene therapy to currently employed modalities of chemotherapy, radiotherapy and surgery attempts to enhance the overall antitumor efficacy and increase the number of complete responders.
It has been reported that MUC1 is expressed in as high as 43% of esophageal adenocarcinoma specimens and that a majority of these specimens were poorly differentiated advanced neoplasms. 30 Transcriptional elements from the DF3/MUC1 gene were used to create a tumorspecific viral promoter that recognizes esophageal adenocarcinoma cells that produce DF3/MUC1. Ad.-DF3.E1.CMV.TNF is a conditionally replication-competent adenoviral vector that non-selectively infects human and rodent cells, but selectively replicates in DF3/ MUC1-producing cells. The expansion of the number of viral particles in a DF3/MUC1-producing cell results in greater TNF-a gene expression that translates into enhanced local TNF-a production. TNF-a has both chemo-sensitizing 31 and radio-sensitizing 32 properties as well as an inherent antitumor effect that is accomplished by coagulative necrosis and capillary destruction. 33 Transcriptional targeting using the DF3 promoter in Ad.DF3.TNF gene therapy drives selective viral replication and enables selective TNF-a gene expression in DF3-producing tumor cells. TNF-a gene therapy focuses delivery of TNF-a to the neoplasm, avoids severe systemic toxicities and therefore may enhance the therapeutic ratio.
We previously demonstrated that TNF-a enhances the antitumor effects of IR in several human tumor cell types. 34 We also reported significant tumor regression following treatment with TNF-a delivered using a replication-deficient adenoviral vector (Ad.Egr.TNF) combined with IR. [35] [36] [37] The Ad.Egr.TNF vector used in our studies contained the radiation-responsive DNA sequences of the EGR1 promoter ligated upstream of the cDNA for human TNF-a. The use of the radiationinducible promoter permitted spatial and temporal control of TNF-a expression within the tumor volume. Tumor cell killing was achieved through a bystander effect and without any increase in normal tissue toxicity when compared with IR treatment alone. 35 With respect to esophageal cancer, the proximity of the esophagus to critical structures, such as the heart and lungs, mandates an even higher specificity of TNF-a expression for the neoplasm while sparing adjacent normal tissues.
Employment of the DF3 tissue-specific promoter in DF3-producing tumors enhances the specificity of the adenoviral vector compared with the EGR1 promoter. The DF3 promoter can be linked with the E1A gene to drive viral replication specifically in DF3-producing cells and therefore result in a conditionally replicationcompetent vector. In addition, the DF3 promoter can also be linked downstream to the cDNA for human TNFa to enhance gene expression of a radio-sensitizing therapeutic cytokine selectively in DF3-producing cells. Replication-competent vectors are advantageous over replication-incompetent vectors in that a reduced number of applications are required to obtain a similar biological effect. Selective TNF-a expression in DF3-producing cancer cells utilizing Ad.DF3.TNF therapy combined with IR may therefore augment local antitumor effects, potentially increasing the number of patients who have a complete pathologic response and subsequently increasing the number of patients who may derive a survival advantage. Selective gene expression using a DF3/MUC1 VK Gupta et al
In the present study, we examined the use of a conditionally replication-competent adenovirus containing the DF3 tissue-specific promoter linked with a therapeutic gene encoding TNF-a in two human esophageal adenocarcinoma cell lines: Bic-1, a DF3-producing cell line and Seg-1, a DF3-non-producing cell line. DF3/MUC1 is a high molecular weight glycoprotein that is aberrantly overexpressed in several epithelial tumors including breast, ovarian, pancreatic, colonic, gastric, and esophageal neoplasms. TNF-a has demonstrated antitumor activity against human and rodent cell lines via a direct apoptotic effect in vitro 38 and results in central hemorrhagic necrosis and modulation of the host immune system in vivo. 39 Animal studies using human tumor xenografts have suggested that TNF-a enhances the tumor's response to radiation. 34 These two elements, the DF3/MUC1 promoter and the TNF-a cDNA, combined in an adenoviral delivery vehicle have produced a vector that is both highly selective and therapeutic in DF3-producing cells and xenografts.
Investigations utilizing a conditionally replicationcompetent adenoviral vector containing the DF3/ MUC1 promoter in a breast carcinoma model have demonstrated selective viral replication in tumor cells expressing the DF3/MUC1 glycoprotein. 20 We have shown that TNF-a production is 15-fold greater in conditioned medium from Bic-1 (DF3/MUC1+) cells and 50-fold greater in tumor homogenates of Bic-1 xenografts compared to Seg-1 (DF3/MUC1À) cells and xenografts. By quantifying TNF-a production, we have indirectly shown that activity of the adenoviral vector containing the DF3/MUC1 promoter, Ad.DF3.TNF, is preferential for the Bic-1 human esophageal cancer cell line compared to the Seg-1 tumor cell line. Additionally, regrowth studies demonstrate that TNF-a production following treatment of Bic-1 xenografts with Ad.DF3.TNF enhances the interactive antitumor response with IR. These findings suggest that the addition of intratumoral Ad.DF3.TNF to conventional antitumor modalities such as radiation may potentiate their therapeutic efficacy in DF3/MUC1-producing tumors.
Transcriptional targeting of tumor cells utilizing a tissue specific-promoter, DF3/MUC1, in adenoviral gene therapy provides a powerful technique to selectively direct viral replication and deliver cDNA segments of TNF-a, a therapeutic gene. A conditionally replicationcompetent adenoviral vector, Ad.DF3-E1A/CMV-TNF may therefore be used to infect specific tumor cells and thus expose these cells to toxic levels of adenovirus and high levels of therapeutic gene expression following viral replication. Increased TNF-a delivery due to vector infection can potentiate the antitumor effects of conventional DNA-damaging therapies such as IR.
Materials and methods
Cell culture
Bic-1 and Seg-1 human esophageal adenocarcinoma cell lines (gift from Dr David Beer, University of Michigan) were grown in Dulbecco's Modified Eagle Medium (DMEM, Gibco RL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, L-glutamine, 100 mg/ml streptomycin and 100 units/ml penicillin. The cell line was incubated at 371C in 7% CO 2 .
Indirect immunofluorescence analysis of the DF3/ MUC1 antigen
Bic-1 and Seg-1 cells (2 Â 10 5 ) were washed with cold phosphate-buffered saline (PBS), incubated with mAb DF3 (1 mg/ml) at 41C for 1 h, and then washed with cold PBS. Cells were incubated with FITC-conjugated goat anti-mouse IgG (Sigma Chemical Co., St Louis, MO, USA) at 41C for 1 h, washed with cold PBS, and then analyzed by flow cytometry. Intensity of the fluorescence was determined for 10 000 cells. Selective gene expression using a DF3/MUC1 VK Gupta et al medium. Conditioned medium was then harvested at days 0, 1, 2, and 5 and stored at -801C. Human tumor necrosis factor alpha enzyme linked immunosorbant assay (hTNF-a ELISA, R&D Systems, Minneapolis, MN, USA) was used to quantify human TNF-a levels within the conditioned medium according to the manufacturer's instructions. Ad.DF3.TNF is a conditionally replication-competent adenoviral vector whereby the E1 gene is under the control of the DF3 promoter. Details of vector structure and production have been previously described. 20 
TNF-a production in
Generation of xenografts
All animal investigations were performed under approved Animal Care Committee (IACUC) protocols at the University of Chicago. Bic-1 and Seg-1 xenografts were produced by injecting 5 Â 10 6 and 3 Â 10 6 cells, respectively, into the subcutaneous space in the right hind limb of athymic nude mice. Xenografts were measured thrice weekly according to the formula length Â width Â height/2. Each tumor volume measurement was compared to its volume at day 0 and expressed as a fractional tumor volume.
TNF-a production in Seg-1 and Bic-1 xenografts
Following the generation of Bic-1 (n ¼ 3) and Seg-1 (n ¼ 3) xenografts, the animals were administered 2 Â 10 8 pu Ad.DF3. TNF directly intratumoral using a Hamilton syringe into five separate sites. The virus was administered as a single dose on day 0. Following CO 2 narcosis, the animals were sacrificed and tumors harvested on day 7. Tumors were snap frozen in liquid nitrogen and stored at -801C. Tumors were thawed and homogenized in 500 ml protein extraction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.5, 5 mM EDTA, pH 7.5, 10 mg/ml aprotinin, 5 mg/ml leupeptin, and 100 mM PMSF) utilizing the Brinkman Polytron homogenizer (Kinematica, AG, Littau, Switzerland) for 30 sec on ice. After four freeze/thaw cycles, tumor homogenates were centrifuged at 41C at 10 000 rpm for 10 min utilizing the RC5C refrigerated centrifuge (Sorvall Instruments Inc., Newtown, CT, USA) with the SS-34 rotor. The pellet was discarded and a standard BioRad macro-protein assay (BioRad Laboratories, Hercules, CA, USA) was performed on the supernatant. Human TNF-a in the supernatant was quantified using hTNF-a ELISA (R&D Systems) according to the manufacturer's instructions.
Xenograft histology
Bic-1 (n ¼ 6) and Seg-1 (n ¼ 6) xenografts generated in athymic nude mice were randomized to treatment with either Ad. DF3.TNF or Ad.DF3.GFP, the null virus containing green fluorescence protein (GFP) at a dose of 2 Â 10 8 pu and then were followed for 21 days. The mice were sacrificed following CO 2 narcosis and the tumors harvested. Representative tumor sections were dissected and snap frozen in OCT (Tissue Tek; Sakura Finetek USA Inc., Torrance, CA, USA). Sections 4 mm in thickness were cut from the OCT blocks and mounted on poly-L-lysine coated slides (Probe-On, Fisher Scientific, Pittsburgh, PA, USA) and then air dried for 30 min. Sections were hydrated in PBS for 5 min and fixed in 1% methanol-free paraformaldehyde (Polysciences, Warrington, PA, USA). After PBS washes, the tissue section was mounted in a glycerol-based mounting medium and examined for green fluorescence protein or counterstained with DAPI by adding one drop of Vectashield with DAPI (Vector, Burlingame, CA, USA) and then examined for nuclear staining. Sections were stained separately due to the DAPI staining interfering with the GFP expression. Fluorescence was determined with a Zeiss photomicroscope equipped with a Hamamatsu digital camera with QED imaging analysis software for the Apple Macintosh 7600. Photographs were colored in Paint Shop Pro 5.0 (Jasc Software, Minneapolis, MN, USA).
Xenograft regrowth studies
Following the generation of Bic-1 (n ¼ 46) and Seg-1 (n ¼ 46) xenografts, animals with a mean xenograft volume of 260 mm 3 were randomized to one of six groups: buffer alone (n ¼ 5), buffer+radiation (n ¼ 5), Ad.DF3. Null (n ¼ 8), Ad.DF3.Null+radiation (n ¼ 10), Ad.DF3.TNF (n ¼ 8), and Ad.DF3.TNF+radiation (n ¼ 10). The adenoviral vectors were administered as a single dose of 2 Â 10 8 pu directly within the tumor using a Hamilton syringe in 10 ml buffer through a single entry point to five separate sites. A total of 10 ml buffer alone was administered in a similar manner to animals in the first two groups. Tumor beds were irradiated using a Pantak PMC 1000 X-ray generator (East Haven, CT, USA) operating at 150 kV and 25 mA at a dose rate of 192 cGy/min. Animals were shielded with lead except for the tumor bearing hind limb. The Bic-1 xenografts received a dose of 4 Gy (Gray) each day on days 0, 1, 2, and 3 (total 16 Gy) and the Seg-1 xenografts a dose of 5 Gy each day on days 0, 1, 2, 3, and 4 (total 25 Gy) determined according to their radiosensitivity curves (Seg-1, D 0 ¼86 cGy; Bic-1, D 0 ¼157 cGy). Groups were compared according to their mean fractional tumor volumes.
Statistical analysis
All values are expressed as the mean 7 standard error of the mean (s.e.m.). Student's t-test was used to determine a statistical significance of 0.05 between mean TNF-a levels in tumor homogenates. Statistical significance between mean tumor volumes of two treatment groups was also demonstrated using Student's t-test.
